Inspire Medical price target raised to $240 from $210 at Lake Street

Lake Street raised the firm’s price target on Inspire Medical to $240 from $210 and keeps a Buy rating on the shares after Inspire provided preliminary Q4 results and 2024 guidance that pointed to a “strong finish” to 2023 and remaining “considerable tailwinds.” The firm expects Inspire can continue to outperform and drive improving leverage and thinks “recent headline noise has provided an attractive buying opportunity,” the analyst tells investors.